NASDAQ: ANIP | Healthcare / Drug Manufacturers / USA |
35.39 | +0.4200 | +1.20% | Vol 96.28K | 1Y Perf 14.62% |
Aug 11th, 2022 16:00 DELAYED |
BID | 14.52 | ASK | 42.88 | ||
Open | 35.33 | Previous Close | 34.97 | ||
Pre-Market | - | After-Market | 35.39 | ||
- - | - -% |
Target Price | 40.67 | Analyst Rating | Moderate Buy 2.00 | |
Potential % | 14.92 | Finscreener Ranking | ★+ 43.87 | |
Insiders Trans % 3/6/12 mo. | -/100/100 | Value Ranking | ★★ 47.35 | |
Insiders Value % 3/6/12 mo. | -/100/100 | Growth Ranking | ★ 34.24 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/100/100 | Income Ranking | — - | |
Price Range Ratio 52W % | 34.50 | Earnings Rating | Neutral | |
Market Cap | 616.71M | Earnings Date | 8th Aug 2022 | |
Alpha | -0.01 | Standard Deviation | 0.12 | |
Beta | 1.01 |
Today's Price Range 34.8235.48 | 52W Range 22.3160.23 | 5 Year PE Ratio Range -410.20213.40 |
Summary:
Buy
Technical Indicators: | Neutral |
Moving Averages: | Strong Buy |
Performance | |||
---|---|---|---|
1 Week | 2.22% | ||
1 Month | 18.64% | ||
3 Months | 41.50% | ||
6 Months | -9.99% | ||
1 Year | 14.62% | ||
3 Years | -50.35% | ||
5 Years | -19.59% | ||
10 Years | 327.42% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -5.75 | |||
ROE last 12 Months | -24.69 | |||
ROA (5Y Avg) | -1.96 | |||
ROA last 12 Months | -10.72 | |||
ROC (5Y Avg) | 1.02 | |||
ROC last 12 Months | -10.27 | |||
Return on invested Capital Q | -2.50 | |||
Return on invested Capital Y | -4.11 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 1.60 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-6.70 | ||||
1.68 | ||||
3.01 | ||||
100.40 | ||||
-4.30 | ||||
-2.66 | ||||
47.06 | ||||
18.64 | ||||
775.44M | ||||
Forward PE | 14.73 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
2.60 | ||||
3.80 | ||||
0.45 | ||||
0.89 | ||||
-4.10 | ||||
Leverage Ratio | 2.30 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
49.20 | ||||
-29.20 | ||||
-6.70 | ||||
-8.50 | ||||
-27.17 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
177.47M | ||||
10.30 | ||||
1.77 | ||||
6.72 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2022 | -0.04 | -0.05 | -25.00 |
Q01 2022 | -0.05 | -0.27 | -440.00 |
Q04 2021 | 0.69 | 0.38 | -44.93 |
Q03 2021 | 0.55 | 0.83 | 50.91 |
Q02 2021 | 0.51 | 0.49 | -3.92 |
Q01 2021 | 0.58 | 0.92 | 58.62 |
Q04 2020 | 0.85 | 0.65 | -23.53 |
Q03 2020 | 0.78 | 0.81 | 3.85 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | 0.04 | 33.33 | Positive |
9/2022 QR | 0.38 | 72.73 | Positive |
12/2022 FY | 0.74 | 27.59 | Positive |
12/2023 FY | 2.35 | 9.81 | Positive |
Next Report Date | - |
Estimated EPS Next Report | -0.04 |
Estimates Count | 2 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 96.28K |
Shares Outstanding | 17.43K |
Shares Float | 9.39M |
Trades Count | 2.26K |
Dollar Volume | 3.39M |
Avg. Volume | 89.15K |
Avg. Weekly Volume | 90.32K |
Avg. Monthly Volume | 76.39K |
Avg. Quarterly Volume | 100.73K |
ANI Pharmaceuticals Inc. (NASDAQ: ANIP) stock closed at 35.39 per share at the end of the most recent trading day (a 1.2% change compared to the prior day closing price) with a volume of 96.28K shares and market capitalization of 616.71M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 338 people. ANI Pharmaceuticals Inc. CEO is Nikhil Lalwani.
The one-year performance of ANI Pharmaceuticals Inc. stock is 14.62%, while year-to-date (YTD) performance is -23.2%. ANIP stock has a five-year performance of -19.59%. Its 52-week range is between 22.31 and 60.2267, which gives ANIP stock a 52-week price range ratio of 34.50%
ANI Pharmaceuticals Inc. currently has a PE ratio of -6.70, a price-to-book (PB) ratio of 1.68, a price-to-sale (PS) ratio of 3.01, a price to cashflow ratio of 100.40, a PEG ratio of 2.32, a ROA of -10.72%, a ROC of -10.27% and a ROE of -24.69%. The company’s profit margin is -27.17%, its EBITDA margin is -6.70%, and its revenue ttm is $177.47 Million , which makes it $10.30 revenue per share.
Of the last four earnings reports from ANI Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.04 for the next earnings report. ANI Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for ANI Pharmaceuticals Inc. is Moderate Buy (2), with a target price of $40.67, which is +14.92% compared to the current price. The earnings rating for ANI Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ANI Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ANI Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 5.55, ATR14 : 1.63, CCI20 : 109.33, Chaikin Money Flow : 0.08, MACD : 1.29, Money Flow Index : 66.29, ROC : 5.80, RSI : 68.22, STOCH (14,3) : 56.03, STOCH RSI : 0.83, UO : 52.01, Williams %R : -43.97), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ANI Pharmaceuticals Inc. in the last 12-months were: Antonio R. Pera (Buy at a value of $126 794), Chad Gassert (Buy at a value of $275 087), Jeanne Thoma (Buy at a value of $49 820), Muthusamy Shanmugam (Buy at a value of $138 252), Nikhil Lalwani (Buy at a value of $199 997), Patrick D. Walsh (Buy at a value of $138 794)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
ANI Pharmaceuticals Inc develops, manufactures and markets generic prescription pharmaceuticals, made in the U.S.A. It manufactures liquid, powder and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone, and Vancomycin.
CEO: Nikhil Lalwani
Telephone: +1 218 634-3500
Address: 210 Main Street West, Baudette 56623, MN, US
Number of employees: 338
Tue, 09 Aug 2022 12:36 GMT ANI Pharmaceuticals (ANIP) Receives a Buy from Raymond James
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.